Shire (NASDAQ: SHPG) and Immune Pharmaceuticals (NASDAQ:IMNP) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.
Shire pays an annual dividend of $0.92 per share and has a dividend yield of 0.6%. Immune Pharmaceuticals does not pay a dividend. Shire pays out 17.3% of its earnings in the form of a dividend.
20.2% of Shire shares are held by institutional investors. Comparatively, 1.6% of Immune Pharmaceuticals shares are held by institutional investors. 2.0% of Shire shares are held by company insiders. Comparatively, 6.7% of Immune Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Shire and Immune Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Shire and Immune Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Shire||$11.40 billion||4.14||$327.40 million||$5.31||29.53|
|Immune Pharmaceuticals||N/A||N/A||-$32.66 million||($4.20)||-0.14|
Shire has higher revenue and earnings than Immune Pharmaceuticals. Immune Pharmaceuticals is trading at a lower price-to-earnings ratio than Shire, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings for Shire and Immune Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Shire currently has a consensus price target of $212.18, indicating a potential upside of 35.30%. Given Shire’s higher possible upside, analysts clearly believe Shire is more favorable than Immune Pharmaceuticals.
Risk & Volatility
Shire has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
Shire beats Immune Pharmaceuticals on 11 of the 14 factors compared between the two stocks.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
What are top analysts saying about Shire? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire and related companies.